Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations

@article{McQueen2018CostEffectivenessOB,
  title={Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations},
  author={R. McQueen and Danielle N. Sheehan and M. Whittington and J. F. V. Boven and Jonathan D. Campbell},
  journal={PharmacoEconomics},
  year={2018},
  volume={36},
  pages={957-971}
}
BackgroundRecently developed asthma biological therapies have been shown to provide relief for severe asthma patients not controlled by inhaled treatment. Given the relatively high costs of biological therapies, cost-effectiveness analyses (CEAs) may be required as a prerequisite for coverage and reimbursement.ObjectiveWe aimed to systematically review published literature on the economic impact of biological asthma therapies and to identify key drivers that impact cost-effectiveness in order… Expand
Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
  • W. C. Anderson, S. Szefler
  • Medicine
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2019
A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
Real-life cost-effectiveness of benralizumab in patients with severe asthma
Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
  • R. Faria, C. McKenna, S. Palmer
  • Medicine
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2014
Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.
Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective
Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma.
  • Mina Tadrous, W. Khuu, +6 authors T. Gomes
  • Medicine
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2018
...
1
2
3
4
5
...